TICKERNERD
Menu
AMGNAMGNHealthcare · Drug Manufacturers - General

AMGN Stock Forecast: Amgen, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$379
−1.63% on the day

The 34 Wall Street analysts covering Amgen, Inc. hold a median 12-month price target of $360 — -5.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 1 Aug 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$204.5B
Ticker Nerd rank
86 / 100
Median analyst target
$360
Analysts covering
34
Total return, dividends reinvested
1W
+0.7%
1M
+1.3%
YTD
+17.4%
1Y
+31.5%
From 52W high
−3.6%
From 52W low
+42.8%
$265
$393
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AMGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Amgen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
86 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Value
90
Quality
87
Momentum
76
Growth
71
Issuance
69
Revisions
62
Accruals
56
Size
1

Volatility (99): The share price has been relatively steady.

Accruals (56): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Amgen, Inc. — and when they’d sell — is the membership.

Wall Street

AMGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AMGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300$350$400Oct 25Jan 26Apr 26Jul 26AMGNHigh $427Median $360Low $215

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says34 analysts
14 Buy17 Hold3 Sell
Low $215Median $360High $427

The green dot is the last close — the median target sits −5.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
29 July 2026BarclaysMaintainsEqual-Weight$350 → $360
13 July 2026GuggenheimMaintainsNeutral—
13 July 2026GuggenheimMaintainsNeutral$340 → $343
13 July 2026UBSMaintainsBuy$400 → $420
13 July 2026UBSMaintainsBuy—
8 July 2026Morgan StanleyMaintainsEqual-Weight$340 → $333
8 July 2026Morgan StanleyMaintainsEqual-Weight—
7 July 2026Truist SecuritiesMaintainsHold$327 → $340
7 July 2026Truist SecuritiesMaintainsHold—
6 July 2026Cantor FitzgeraldReiteratesNeutral—
6 July 2026Cantor FitzgeraldReiteratesNeutral$350
16 June 2026MizuhoMaintainsNeutral—
10 June 2026Morgan StanleyMaintainsEqual-Weight—
14 May 2026Piper SandlerMaintainsOverweight—
4 May 2026GuggenheimMaintainsNeutral—
1 May 2026Truist SecuritiesMaintainsHold—
21 Apr 2026Canaccord GenuityInitiatesHold—
13 Apr 2026UBSMaintainsBuy—
10 Apr 2026Morgan StanleyMaintainsEqual-Weight—
9 Apr 2026GuggenheimMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

AMGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.1%
Analysts raising
1
Analysts cutting
0
Fundamentals

Amgen, Inc. (AMGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
26.4×

Cheaper than 31% of US stocks

Price / sales
5.5×

Cheaper than 23% of US stocks

Price / book
22.2×

Cheaper than 5% of US stocks

EV / EBITDA
15.0×

Cheaper than 24% of US stocks

Growth & margins
Revenue growth (YoY)
5.8%

Higher than 43% of US stocks

Earnings growth (YoY)
5.1%

Higher than 43% of US stocks

Gross margin
68.2%

Higher than 82% of US stocks

Operating margin
33.8%

Higher than 90% of US stocks

Net margin
21.0%

Higher than 83% of US stocks

Returns & dividend
Return on equity
101.3%

Higher than 96% of US stocks

Return on assets
8.3%

Higher than 89% of US stocks

Dividend yield
2.7%

Higher than 58% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AMGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
AMGNAmgen, Inc.$204.5B
86
GILDGilead Sciences, Inc.$161.6B
89
PFEPfizer Inc.$142.2B
69
MRKMerck & Co., Inc.$323.2B
69
BMYBristol Myers Squibb Co.$133.0B
99
ABBVAbbVie, Inc.$443.4B
91
JNJJohnson & Johnson$617.4B
94
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest AMGN news & analysis

Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?

Zacks Investment Research · 3 Aug 2026neutral

The second-quarter 2026 earnings reporting cycle for the Medical sector is now underway, encompassing pharmaceutical, biotech, and medical device companies. An article identifies five pharma stocks that may exceed Q2 earnings forecasts.

Why it matters — As a company within the Medical sector's pharma/biotech segment, Amgen watchers would be interested in sector-wide earnings coverage that could draw attention to Q2 reporting.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks Investment Research · 3 Aug 2026neutral

Zacks Investment Research published an article highlighting how its Zacks Earnings ESP tool can help identify medical stocks, including Amgen, that are expected to beat quarterly earnings estimates.

Why it matters — AMGN watchers would care because the article suggests the stock may be positioned to outperform on its next earnings report, based on the proprietary screening tool.

Amgen discloses data breach, says patient information was stolen

Reuters · 31 July 2026negative

Amgen disclosed in a regulatory filing on Friday that it suffered a cybersecurity breach in which hackers stole company data and patient health information from cloud storage systems run by third-party providers.

Why it matters — A data breach involving stolen patient health information poses regulatory, reputational, and legal risks for Amgen.

Amgen Q2 Earnings Preview: Will the Beat Streak Continue?

Zacks Investment Research · 31 July 2026neutral

As Amgen prepares to report second-quarter earnings, the article notes the company has a history of exceeding expectations, with investors focused on trends in key drug sales and any updates on the obesity candidate MariTide.

Why it matters — The preview flags two areas that can move the stock—whether core drug sales hold up and whether Amgen signals progress on MariTide, a potential major growth driver.

AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND

PRNewsWire · 30 July 2026positive

Amgen announced that its Board of Directors declared a $2.52 per share dividend for the third quarter of 2026.

Why it matters — The dividend declaration signals continued cash returns to shareholders, which is relevant for income-focused investors tracking Amgen's payout trajectory.

FAQ

Frequently asked questions about AMGN stock

What is the AMGN stock price forecast for 2026-2027?

The 34 Wall Street analysts covering Amgen, Inc. have a median 12-month price target of $360, with estimates ranging from $215 to $427. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AMGN stock a buy right now?

Of the 34 analysts covering Amgen, Inc., 14 rate it a Buy, 17 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Amgen, Inc. 86 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AMGN?

As at 1 Aug 2026, Amgen, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will AMGN stock go up?

No one can know that. What the data says: the median 12-month target from 34 analysts implies -5.0% from the last close, and Ticker Nerd's factor model ranks Amgen, Inc. 86 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AMGN stock forecast for 2030?

No analyst covering Amgen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $215 to $427 over the next 12 months.

How has AMGN stock performed over the past year?

Amgen, Inc. returned +31.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Amgen, Inc. do?

Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics worldwide.

What is the latest news on AMGN?

The most recent item we track (Zacks Investment Research, 3 Aug 2026): "Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?". The second-quarter 2026 earnings reporting cycle for the Medical sector is now underway, encompassing pharmaceutical, biotech, and medical device companies. An article identifies five pharma stocks that may exceed Q2 earnings forecasts.

Company

About Amgen, Inc.

Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on innovative medicines addressing serious illnesses in areas such as oncology, inflammation, cardiovascular disease, bone health, nephrology, and neurology. Key products target conditions like cancer, rheumatoid arthritis, osteoporosis, anemia, and migraines, providing treatments that help manage chronic diseases and improve patient outcomes. Amgen Inc. serves healthcare providers including physicians, clinics, dialysis centers, hospitals, and pharmacies, distributing its portfolio through pharmaceutical wholesale distributors. The company also engages in collaborations, such as partnerships for development and commercialization of specific therapies. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen Inc. plays a vital role in the biotechnology sector by advancing biologic medicines that address unmet medical needs and contribute to global healthcare advancements.

CEO Mr. Robert A. Bradway · 31,500 employees · United States · https://www.amgen.com